Consolidation of metabolomic, proteomic, and GWAS data in connective model of schizophrenia

[1]  Suzanne E. Schindler,et al.  Comparative Analysis of Alzheimer's Disease Cerebrospinal Fluid Biomarkers Measurement by Multiplex SOMAscan Platform and Immunoassay-Based Approach. , 2022, Journal of Alzheimer's disease : JAD.

[2]  B. Camarena,et al.  Insights into myelin dysfunction in schizophrenia and bipolar disorder , 2022, World journal of psychiatry.

[3]  A. Brazma,et al.  The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences , 2021, Nucleic Acids Res..

[4]  Arthur T. Kopylov,et al.  Convolutional neural network in proteomics and metabolomics for determination of comorbidity between cancer and schizophrenia , 2021, J. Biomed. Informatics.

[5]  Ming Li,et al.  Genome wide association study identifies four loci for early onset schizophrenia , 2021, Translational Psychiatry.

[6]  I. Sommer,et al.  Estrogens in schizophrenia: progress, current challenges and opportunities , 2021, Current opinion in psychiatry.

[7]  N. Bokhan,et al.  Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia , 2020, Neuropsychiatric disease and treatment.

[8]  A. Kopylov,et al.  Association of Proteins Modulating Immune Response and Insulin Clearance during Gestation with Antenatal Complications in Patients with Gestational or Type 2 Diabetes Mellitus , 2020, Cells.

[9]  Kai Wang,et al.  The proteome and its dynamics: A missing piece for integrative multi-omics in schizophrenia , 2020, Schizophrenia Research.

[10]  R. Deshmukh,et al.  Resistance to Checkpoint Inhibition in Cancer Immunotherapy , 2020, Translational oncology.

[11]  O. Reiner,et al.  Complement System in Brain Architecture and Neurodevelopmental Disorders , 2020, Frontiers in Neuroscience.

[12]  A. Lisitsa,et al.  Revelation of Proteomic Indicators for Colorectal Cancer in Initial Stages of Development , 2020, Molecules.

[13]  M. Thevis,et al.  Detecting the misuse of 7-oxo-DHEA by means of carbon isotope ratio mass spectrometry in doping control analysis. , 2020, Rapid communications in mass spectrometry : RCM.

[14]  Takahiko Nagamine.  Role of Norepinephrine in Schizophrenia: An Old Theory Applied to a New Case in Emergency Medicine. , 2020, Innovations in clinical neuroscience.

[15]  A. Köttgen,et al.  Human C-terminal CUBN variants associate with chronic proteinuria and normal renal function. , 2019, The Journal of clinical investigation.

[16]  Z. Gan,et al.  Rapid cycling bipolar disorder is associated with antithyroid antibodies, instead of thyroid dysfunction , 2019, BMC Psychiatry.

[17]  M. Álvarez-Ariza,et al.  Proteomics in Schizophrenia: A Gateway to Discover Potential Biomarkers of Psychoneuroimmune Pathways , 2019, Front. Psychiatry.

[18]  Eric W. Deutsch,et al.  Human Proteome Project Mass Spectrometry Data Interpretation Guidelines 3.0 , 2019, bioRxiv.

[19]  S. Banka,et al.  Profound vitamin D deficiency in four siblings with Imerslund‐Grasbeck syndrome with homozygous CUBN mutation , 2019, JIMD reports.

[20]  P. Newhouse,et al.  The Role of Estrogen in Brain and Cognitive Aging , 2019, Neurotherapeutics.

[21]  C. Ross,et al.  Increased Protein Insolubility in Brains From a Subset of Patients With Schizophrenia. , 2019, The American journal of psychiatry.

[22]  J. Fyfe,et al.  Inherited selective cobalamin malabsorption in Komondor dogs associated with a CUBN splice site variant , 2018, BMC Veterinary Research.

[23]  J. Nickerson,et al.  Dopamine-dependent cognitive processes after menopause: the relationship between COMT genotype, estradiol, and working memory , 2018, Neurobiology of Aging.

[24]  S. Kaneko,et al.  Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population , 2018, Scientific Reports.

[25]  T. Zhao,et al.  Subclinical hypothyroidism and depression: a meta-analysis , 2018, Translational Psychiatry.

[26]  Philipp E. Geyer,et al.  Proteomics for blood biomarker exploration of severe mental illness: pitfalls of the past and potential for the future , 2018, Translational Psychiatry.

[27]  Ching-Hua Lin,et al.  Schizophrenia in type 2 diabetes mellitus: Prevalence and clinical characteristics , 2018, European Psychiatry.

[28]  A. Moustafa,et al.  Testosterone, DHEA and DHEA-S in patients with schizophrenia: A systematic review and meta-analysis , 2018, Psychoneuroendocrinology.

[29]  T. Weickert,et al.  Considering the role of adolescent sex steroids in schizophrenia , 2018, Journal of neuroendocrinology.

[30]  Aoife O'Gorman,et al.  A systematic review of metabolite biomarkers of schizophrenia , 2017, Schizophrenia Research.

[31]  A. Koyanagi,et al.  Psychotic experiences and disability: Findings from the Collaborative Psychiatric Epidemiology Surveys , 2017, Schizophrenia Research.

[32]  Panos Roussos,et al.  Microvascular anomaly conditions in psychiatric disease. Schizophrenia – angiogenesis connection , 2017, Neuroscience & Biobehavioral Reviews.

[33]  Narayan R. Mutalik,et al.  Fractional protein study in chronic schizophrenics – A Case control study , 2017 .

[34]  B. Dean,et al.  Progesterone: The neglected hormone in schizophrenia? A focus on progesterone-dopamine interactions , 2016, Psychoneuroendocrinology.

[35]  J. Kuratsu,et al.  Macrophage-Derived Angiopoietin-Like Protein 2 Exacerbates Brain Damage by Accelerating Acute Inflammation after Ischemia-Reperfusion , 2016, PloS one.

[36]  W. Fleischhacker,et al.  Psychotic disorders in DSM-5 and ICD-11 , 2016, CNS Spectrums.

[37]  C. Klinge,et al.  Novel mechanisms for DHEA action. , 2016, Journal of molecular endocrinology.

[38]  J. Nyengaard,et al.  Spatiotemporal patterns of sortilin and SorCS2 localization during organ development , 2016, BMC Cell Biology.

[39]  D. Currò,et al.  Thyroid Hormones, Oxidative Stress, and Inflammation , 2016, Mediators of inflammation.

[40]  L. DeLisi,et al.  Quantitative Trait Locus and Brain Expression of HLA-DPA1 Offers Evidence of Shared Immune Alterations in Psychiatric Disorders , 2016, Microarrays.

[41]  Giulio Genovese,et al.  Schizophrenia risk from complex variation of complement component 4 , 2016, Nature.

[42]  E. Severance,et al.  Role of Immune and Autoimmune Dysfunction in Schizophrenia , 2015, Handbook of Behavioral Neuroscience.

[43]  A. Fresán,et al.  No association between ApoE and schizophrenia: Evidence of systematic review and updated meta-analysis , 2015, Schizophrenia Research.

[44]  P. Xie,et al.  Comparative proteomic analysis of plasma from bipolar depression and depressive disorder: identification of proteins associated with immune regulatory , 2015, Protein & Cell.

[45]  B. H. Miller,et al.  Epigenetic mechanisms in schizophrenia. , 2015, Progress in biophysics and molecular biology.

[46]  M. Keshavan,et al.  Can age at sexual maturity act as a predictive biomarker for prodromal negative symptoms? , 2015, Schizophrenia Research.

[47]  W. van den Brink,et al.  Impact of DSM-5 changes on the diagnosis and acute treatment of schizophrenia. , 2015, Schizophrenia bulletin.

[48]  J. Nascimento,et al.  The proteome of schizophrenia , 2015, npj Schizophrenia.

[49]  M. Goodarzi,et al.  DHEA, DHEAS and PCOS , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[50]  Tamara S. Roman,et al.  New genetic loci link adipose and insulin biology to body fat distribution , 2014, Nature.

[51]  Martina Sattlecker,et al.  Are blood-based protein biomarkers for Alzheimer's disease also involved in other brain disorders? A systematic review. , 2014, Journal of Alzheimer's disease : JAD.

[52]  Tyrone D. Cannon,et al.  Towards a Psychosis Risk Blood Diagnostic for Persons Experiencing High-Risk Symptoms: Preliminary Results From the NAPLS Project , 2014, Schizophrenia bulletin.

[53]  T. Maniatis,et al.  An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex , 2014, The Journal of Neuroscience.

[54]  M. Nishihara,et al.  Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice , 2014, Acta neuropathologica communications.

[55]  Massimo Castagnola,et al.  Characterization of salivary proteins of schizophrenic and bipolar disorder patients by top-down proteomics. , 2014, Journal of proteomics.

[56]  Daniel Martins-de-Souza,et al.  Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder , 2014, Dialogues in clinical neuroscience.

[57]  Stephan Heckers,et al.  Definition and description of schizophrenia in the DSM-5 , 2013, Schizophrenia Research.

[58]  Robert V Farese,et al.  Dissociation of Frontotemporal Dementia–Related Deficits and Neuroinflammation in Progranulin Haploinsufficient Mice , 2013, The Journal of Neuroscience.

[59]  S. Miyamoto,et al.  Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents , 2012, Molecular Psychiatry.

[60]  Steven Finkbeiner,et al.  Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. , 2012, The Journal of clinical investigation.

[61]  G. He,et al.  Label-free quantitative proteomic analysis reveals dysfunction of complement pathway in peripheral blood of schizophrenia patients: evidence for the immune hypothesis of schizophrenia. , 2012, Molecular bioSystems.

[62]  L. Petrucelli,et al.  Progranulin regulates neuronal outgrowth independent of Sortilin , 2012, Molecular Neurodegeneration.

[63]  Michael D. Spain,et al.  Identification of a biological signature for schizophrenia in serum , 2012, Molecular Psychiatry.

[64]  H. Nicolini,et al.  Monoamine Oxidase A and B Gene Polymorphisms and Negative and Positive Symptoms in Schizophrenia , 2012, ISRN psychiatry.

[65]  M. Akiibinu,et al.  Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics , 2012, BMC Research Notes.

[66]  Y. Fang,et al.  Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. , 2011, Journal of proteome research.

[67]  Andrea Ballabio,et al.  TFEB Links Autophagy to Lysosomal Biogenesis , 2011, Science.

[68]  J. Thome,et al.  Profiling for novel proteomics biomarkers in neurodevelopmental disorders , 2011, Expert review of proteomics.

[69]  B. Dean,et al.  The neurobiology of APOE in schizophrenia and mood disorders. , 2011, Frontiers in bioscience.

[70]  P. Falkai,et al.  Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. , 2010, Journal of psychiatric research.

[71]  T. Aittokallio,et al.  An update on clinical proteomics in Alzheimer’s research , 2010, Journal of neurochemistry.

[72]  Lan Wang,et al.  Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients , 2010, Molecular Psychiatry.

[73]  C. Iadecola,et al.  Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice , 2010, The Journal of experimental medicine.

[74]  F. Ortega,et al.  Inverse relation between FASN expression in human adipose tissue and the insulin resistance level , 2010, Nutrition & metabolism.

[75]  Michael D. Spain,et al.  Validation of a Blood-Based Laboratory Test to Aid in the Confirmation of a Diagnosis of Schizophrenia , 2010, Biomarker insights.

[76]  A. Nica,et al.  Hyperthyroidism–cause of depression and psychosis: a case report , 2009, Journal of medicine and life.

[77]  E Holmes,et al.  Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder , 2009, Molecular Psychiatry.

[78]  Wagner F. Gattaz,et al.  Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia , 2009, European Archives of Psychiatry and Clinical Neuroscience.

[79]  D. Weinberger,et al.  The complement system in schizophrenia. , 2008, Drug news & perspectives.

[80]  T. Kašpárek,et al.  Testosterone in first-episode schizophrenia. , 2007, Neuro endocrinology letters.

[81]  M. Mimmack,et al.  Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. , 2007, The international journal of neuropsychopharmacology.

[82]  P. Parzer,et al.  Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia , 2007, Psychological Medicine.

[83]  D. Reich,et al.  Population Structure and Eigenanalysis , 2006, PLoS genetics.

[84]  M. De Hert,et al.  Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. , 2006, Clinical practice and epidemiology in mental health : CP & EMH.

[85]  V. Haroutunian,et al.  Variations in differential gene expression patterns across multiple brain regions in schizophrenia , 2005, Schizophrenia Research.

[86]  J. Karbowska,et al.  Effect of DHEA on endocrine functions of adipose tissue, the involvement of PPAR gamma. , 2005, Biochemical pharmacology.

[87]  D. Grobbee,et al.  Endogenous oestrogens are related to cognition in healthy elderly women , 2005, Clinical endocrinology.

[88]  Kenichi Yamamoto,et al.  Proposal for a noradrenaline hypothesis of schizophrenia , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[89]  L. Kahn,et al.  Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects , 2003, Psychoneuroendocrinology.

[90]  T. Hanafusa,et al.  In vivo activation of the constitutive androstane receptor beta (CARbeta) by treatment with dehydroepiandrosterone (DHEA) or DHEA sulfate (DHEA-S). , 2002, FEBS letters.

[91]  A. Heinz,et al.  Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain , 2002, Molecular Psychiatry.

[92]  A Carlsson,et al.  Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. , 2001, Annual review of pharmacology and toxicology.

[93]  G. Garcı́a-Cardeña,et al.  Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. , 1997, The Journal of clinical investigation.

[94]  S. Arnold,et al.  Further Evidence of Abnormal Cytoarchitecture of the Entorhinal Cortex in Schizophrenia Using Spatial Point Pattern Analyses , 1997, Biological Psychiatry.

[95]  A. Kaviani,et al.  Time course of altered thyroid states on 5-HT1A receptors and 5-HT uptake sites in rat brain: an autoradiographic analysis. , 1993, Neuroendocrinology.

[96]  D. Kammen,et al.  Dopamine and norepinephrine activity in schizophrenia An intergrative perspective , 1991, Schizophrenia Research.